U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Development Tool (DDT) Qualification Programs
  5. Biomarker Qualification Program
  6. Biomarker Full Qualification Package
  1. Biomarker Qualification Program

Biomarker Full Qualification Package

Download
Full Qualification Package (PDF - 162KB)

Learn More

Contact Us
CDER-BiomarkerQualificationProgram@fda.hhs.gov
301-796-2600

Below is a suggested template that requestors may modify to accommodate their submission data, as needed:

  1. Executive Summary
  2. Background
  3. Proposed Context of Use (COU)
  4. Summary of Supporting Data
  5. Methodologies
  6. Results
  7. Appendices

  1. Executive Summary

  2. Background

    • Importance of the specified biomarker as a drug development tool
    • The background for the disease and/or organ toxicity

  3. Proposed Context of Use (COU)

    • Proposed COU (Use Statement and Conditions for Qualified Use) to include:
      • Disease area/organ toxicity
      • Targeted population

  4. Summary of Supporting Data

    • Supportive nonclinical and clinical studies
    • Additional evidence from published literature

  5. Methodologies

    • Performance characteristics and methodologies of the analytically validated biomarker assays used
    • Imaging modalities, as applicable
    • Chart, graphs, plots, flowcharts etc., as applicable
    • Data collection and analysis methodologies such as analysis endpoint/s, baseline data, missing data, sensitivity analysis etc.
    • Statistical Analysis Plan
    • Codes such as SAS codes used in data analyses, as applicable

  6. Results

    • Raw data from clinical/nonclinical studies, protocols, testing conditions, populations tested, and the outcome of the performed study
    • All data sources, datasets (exploratory, confirmatory etc.), Registry and database(s)
    • A report that combines results from all studies, analyses (statistical and modeling) and conclusions
    • A conclusion summary that describes key findings from all the studies conducted and discusses how the key findings support the use of the proposed biomarker as a drug development tool.

  7. Appendices

    • Any supporting material such as references, peer-reviewed literature, summaries or statements from other regulatory agencies, academia, consortia, medical boards that may highlight the use of biomarkers
    • Upon qualification, reviews of the submitted qualification package and the qualification recommendation will be available on the Biomarker Qualification Program website. Please include a statement acknowledging that you are aware of this plan and do not object to written summary reviews being made publicly available.

 

For downloadable version:

 

Back to Top